European Investor
20 Nov 2026, 18:27
Merck’s Sac-TMT Meets Overall Survival Endpoint in Phase 3 Gastroesophageal Cancer Trial
Merck (NYSE: MRK) said its Phase 3 TroFuse-015 trial of sacituzumab tirumotecan met its primary endpoint of overall survival in patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who had received at least two prior lines of systemic therapy.
Sac-TMT produced a statistically significant and clinically meaningful improvement in overall survival versus physician’s choice of trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel. Results were generally consistent across subgroups regardless of TROP2 expression status. However, the drug did not meet the secondary endpoint of progression-free survival.
The study enrolled 473 patients and marks the second positive Phase 3 readout from Merck’s global TroFuse development program. Sac-TMT is being evaluated across 18 ongoing Phase 3 trials in multiple tumor types, including gastric, breast, bladder, lung, ovarian and endometrial cancers.
The result is an important clinical catalyst for Merck’s oncology pipeline because sac-TMT is the first TROP2-directed antibody-drug conjugate to demonstrate an overall survival benefit in a global Phase 3 study in this patient population. Merck plans to present the data at an upcoming medical meeting and discuss them with regulatory authorities.
Merck (NYSE: MRK) said its Phase 3 TroFuse-015 trial of sacituzumab tirumotecan met its primary endpoint of overall survival in patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who had received at least two prior lines of systemic therapy.
Sac-TMT produced a statistically significant and clinically meaningful improvement in overall survival versus physician’s choice of trifluridine-tipiracil, irinotecan, paclitaxel or docetaxel. Results were generally consistent across subgroups regardless of TROP2 expression status. However, the drug did not meet the secondary endpoint of progression-free survival.
The study enrolled 473 patients and marks the second positive Phase 3 readout from Merck’s global TroFuse development program. Sac-TMT is being evaluated across 18 ongoing Phase 3 trials in multiple tumor types, including gastric, breast, bladder, lung, ovarian and endometrial cancers.
The result is an important clinical catalyst for Merck’s oncology pipeline because sac-TMT is the first TROP2-directed antibody-drug conjugate to demonstrate an overall survival benefit in a global Phase 3 study in this patient population. Merck plans to present the data at an upcoming medical meeting and discuss them with regulatory authorities.